Takeda’s new deal with Kumquat; IL-2 biotech raises $55M

Plus, news about Neu­ro­crine Bio­sciences, Nx­era Phar­ma, Voy­ager Ther­a­peu­tics and Acor­da Ther­a­peu­tics:

Take­da inks pact with Kumquat: The San Diego biotech will get up to $130 mil­lion in the near term and could re­ceive more than $1.2 bil­lion in biobucks for li­cens­ing its oral small mol­e­c­u­lar in­hibitor to Take­da. The com­pa­nies shared few de­tails about what tar­get and in­di­ca­tions they plan to pur­sue. Or­biMed-backed Kumquat Bio­sciences will lead Phase 1; then Take­da will take over. — Kyle LaHu­cik

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.